Cangrelor

Mechanism of Action

Cangrelor, a novel non–thienopyridine adenosine triphosphate (ATP) analog, exerts its antiplatelet effects through a specific mechanism of action. Cangrelor inhibits blood platelet activation and aggregation, ultimately reducing the risk of thrombotic events.

The primary mechanisms of action of cangrelor include:

• P2Y12 receptor antagonism: Cangrelor is a reversible antagonist of the P2Y12 receptor, an essential receptor involved in platelet activation and aggregation. By binding to the P2Y12 receptor on platelets, cangrelor effectively blocks the binding of adenosine diphosphate (ADP), a potent platelet activator (see Image. Cangrelor Mechanism of Action). This action leads to inhibition of the ADP-mediated signaling pathway and subsequent platelet activation.[12]
• Rapid onset and offset of action: Cangrelor exhibits a rapid onset of action, reaching maximum platelet inhibition within minutes of administration. This quick onset renders the drug particularly useful in the acute setting of PCI, where immediate platelet inhibition is essential. Moreover, cangrelor's effects are rapidly reversible upon discontinuation, resulting in a shorter duration of action than those of other antiplatelet agents.[13]
• Platelet inhibition without metabolism: Unlike oral antiplatelet agents such as clopidogrel or ticagrelor, cangrelor does not rely on metabolic activation. Cangrelor is administered as an intravenous infusion directly into the bloodstream, eliminating the need for hepatic metabolism. This unique characteristic of cangrelor ensures consistent platelet inhibition without interpatient variability.
• Preservation of vascular function: Cangrelor selectively inhibits the P2Y12 receptor on platelets while leaving other ADP receptors unaffected. This selectivity helps preserve endothelial function and maintain the balance between antithrombotic effects and the physiological hemostatic response. Additionally, cangrelor inhibits platelets without compromising the overall integrity of the vascular system.

In summary, cangrelor is a potent and reversible intravenous P2Y12 inhibitor that acts directly and has a short duration of action. Cangrelor quickly inhibits platelet function upon administration and restores normal platelet function within 1 hour of discontinuation. Cangrelor is effective at reducing the risk of stent thrombosis, especially in patients not pretreated with a P2Y12 inhibitor. In addition, cangrelor may be particularly useful in clinical situations where oral P2Y12 inhibitor absorption is not feasible or unreliable (eg, hemodynamic instability, vomiting, or intubation).[8]

Results from a meta-analysis of the CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX Trials provided substantial support for these observations, indicating a decreased incidence of the combined outcome of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis within 48 hours with cangrelor use compared with clopidogrel. Furthermore, cangrelor was associated with a 41% reduction in stent thrombosis. Although significant bleeding events were comparable between the 2 cohorts, minor bleeding occurred more frequently in the cangrelor group.[14]

Pharmacokinetics

Understanding the pharmacokinetic profile of cangrelor is essential for appropriate dosing, monitoring, and optimizing therapeutic outcomes. The key aspects of cangrelor pharmacokinetics are as follows:

Route of administration: Cangrelor is administered intravenously as a continuous infusion. The intravenous route enables rapid and predictable drug delivery, ensuring immediate platelet inhibition during and after PCI.[15]

Absorption: As cangrelor is administered intravenously, it is fully and immediately available in the systemic circulation, bypassing gastrointestinal tract absorption, resulting in a peak plasma concentration within 2 minutes of administration.

Distribution: Cangrelor distributes rapidly throughout the bloodstream, facilitated by its high water solubility and a volume of distribution of 3.9 L. Approximately 97% to 98% of the drug binds to plasma proteins. Notably, cangrelor binds extensively to platelets, primarily via the P2Y12 receptor, enabling it to reach its site of action and exert potent antiplatelet effects.

Metabolism:  Cangrelor undergoes primary metabolism via nonenzymatic hydrolysis in blood plasma, resulting in dephosphorylation. This rapid and spontaneous degradation leads to the formation of an inactive metabolite. Cangrelor metabolism occurs independently of hepatic enzymes and does not involve the cytochrome P450 system.

Elimination: Cangrelor and its metabolite are primarily eliminated through renal excretion, with a plasma clearance of about 43 L/h. The elimination half-life of cangrelor is relatively short, averaging about 3 to 6 minutes.[16] This short half-life allows rapid drug elimination, rendering cangrelor suitable for situations requiring prompt platelet inhibition.

Clinical implications: The favorable pharmacokinetic profile of cangrelor, characterized by a short half-life and rapid reversibility, has significant clinical implications. Healthcare professionals can benefit from its predictable, controllable pharmacokinetics, which enables them to adjust and titrate the infusion rate as needed during PCI procedures.

Administration

Cangrelor is available in a parenteral dosage form, specifically as a lyophilized powder for intravenous infusion. The lyophilized powder is reconstituted with a suitable diluent to prepare a solution for intravenous administration. Cangrelor is typically supplied in vials or single-use infusion bags.

Available Dosage Forms

Cangrelor is available as an intravenous infusion.

Strength

The available strength of cangrelor is 50 mg/vial.

Adult Dosage

Loading dose: A cangrelor loading dose is usually administered before initiating the infusion to ensure rapid onset of platelet inhibition. The recommended loading dose of cangrelor is 30 µg/kg, given as a bolus injection over a short duration, such as 1 minute.[17]

Continuous infusion: Following the loading dose, cangrelor is initiated as a continuous infusion. The infusion rate is adjusted according to the patient's weight to maintain therapeutic platelet inhibition. The recommended infusion rate of 4 µg/kg/min allows continuous cangrelor administration throughout the PCI procedure or for up to 2 hours after the procedure, whichever is longer.

Adjustment of dosing: The cangrelor infusion rate can be adjusted based on individual patient factors, including response to therapy, bleeding risk, and PCI procedure complexity. Dosing may need to be titrated up or down to achieve the desired level of platelet inhibition while carefully managing the risk of bleeding complications.

Bridging therapy dosing: A 0.75 µg/kg/min infusion was established in the Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery (BRIDGE) trial for patients awaiting coronary artery bypass graft surgical procedures.

Duration of therapy:  Cangrelor therapy is typically limited to the PCI procedure and the immediate postprocedural period. Upon completion of the PCI procedure, patients are often transitioned to oral antiplatelet agents, such as clopidogrel 600 mg, ticagrelor 180 mg, or prasugrel 60 mg, for long-term maintenance therapy.[18][19]

Specific Patient Populations

Hepatic impairment:  Cangrelor has not been specifically studied in patients with hepatic impairment. Because cangrelor metabolism is not dependent on hepatic function, dosage adjustment is not necessary for patients with hepatic impairment.[20]

Renal impairment: Typically, no dosage adjustment is necessary for patients with mild, moderate, or severe renal impairment when using cangrelor. However, close monitoring for potential adverse effects and platelet inhibition response is strongly recommended.

Pregnancy considerations: Limited clinical data are available on the use of cangrelor during pregnancy. In pregnant patients requiring intervention, intravenous heparin is the preferred anticoagulant.[21] Because the safety of cangrelor for both the mother and the developing fetus has not been established, cangrelor use during pregnancy should be avoided unless the potential benefits outweigh the risks.

Breastfeeding considerations:  Limited data exist on the excretion of cangrelor in human milk and its potential effects on breastfed infants. Therefore, caution is warranted when considering the use of cangrelor during lactation.[20]

Pediatric patients: The safety and effectiveness of cangrelor have not been established in the pediatric population. 

Older adult patients:  Typically, no dosage adjustment is required. Patients aged 75 years and older have a higher risk of moderate to severe bleeding, which is approximately 3-fold greater than the risk in younger patients. However, compared with clopidogrel, cangrelor provides comparable effectiveness in patients both older and younger than 75 years without increasing the risk of significant bleeding.[22]

Adverse Effects

Like other medications, cangrelor can potentially cause adverse drug reactions in some patients.[23] Common adverse drug reactions associated with cangrelor use are listed below:

• Bleeding:  The most common adverse effect of cangrelor is bleeding, ranging from minor events, such as epistaxis or bruising, to more severe bleeding. Bleeding may occur at the site of vascular access, surgical sites, or other locations in the body.

• Thrombocytopenia: Cangrelor can lead to thrombocytopenia, which may increase the risk of bleeding.[24]

• Hypersensitivity reactions: Cangrelor may cause hypersensitivity or allergic reactions in some patients, which may present as a skin rash, itching, hives, or swelling.

• Nausea and vomiting: Cangrelor may cause gastrointestinal symptoms in some patients, including nausea and vomiting.

• Hypotension: Cangrelor can potentially lower blood pressure, which may lead to hypotension. Therefore, healthcare professionals should closely monitor patients' blood pressure during cangrelor administration.

• Local site reactions: In some cases, patients may experience reactions at the injection or infusion site, including pain, redness, or swelling.

Drug-Drug Interactions

Glycoprotein IIb/IIIa inhibitors

Cangrelor should not be coadministered with glycoprotein 2b/3a inhibitors, such as abciximab, eptifibatide, or tirofiban, because this combination may increase bleeding risk.[25]

P2Y12 inhibitors

Cangrelor should be used cautiously with other P2Y12 inhibitors, such as clopidogrel, ticagrelor, and prasugrel. Cangrelor is known for its high P2Y12 receptor affinity, which prevents other P2Y12 agents from binding to the receptor. Consequently, additional P2Y12 inhibitors administered during cangrelor infusion may be unable to bind to the P2Y12 receptor, resulting in a lack of antiplatelet effects and ischemic protection.[11] Specific recommendations for switching from intravenous cangrelor to oral P2Y12 inhibitors are listed below.

• Clopidogrel: During cangrelor infusion, high receptor occupancy prevents the binding of clopidogrel's active metabolite to the P2Y12 receptor, leading to a lack of platelet inhibitory effect. Clopidogrel is administered at the end of the cangrelor infusion to avoid this interaction, allowing sufficient time for cangrelor to wash out from the system and subsequent binding of clopidogrel's active metabolite to the P2Y12 receptor. Therefore, clopidogrel should be administered after the discontinuation of cangrelor infusion to avoid drug interactions.[26]

• Ticagrelor:  Due to its extended systemic half-life and that of its major metabolite, ticagrelor can be safely administered at any time, whether before, during, or after cangrelor infusion, without significant drug interactions. Results from the Switching Antiplatelet 5 (SWAP-5) study, which specifically investigated cangrelor use in patients pretreated with ticagrelor, indicated that administering cangrelor to patients pretreated with ticagrelor enhanced platelet inhibition without any noticeable differences in pharmacokinetic or pharmacodynamic profiles upon discontinuing the drug infusion. Moreover, results from this study showed no significant drug interactions between cangrelor and ticagrelor.[27] 

• Prasugrel: The transition from cangrelor to prasugrel should occur after the infusion is discontinued to avoid potential drug interactions. For an effective transition, initiating the shift approximately 30 minutes before the cangrelor infusion is completed is advisable.[28] International expert consensus recommends early administration of ticagrelor during percutaneous coronary intervention to minimize the potential gap in platelet inhibition during the transition from cangrelor infusion.[29]

Results from in vitro studies showed that cangrelor does not inhibit cytochrome P450 enzymes at therapeutic concentrations. Consequently, cangrelor administration is not anticipated to interfere with the hepatic metabolism of other concurrently administered therapeutic agents.[30]

Thrombolytic agents

Cangrelor requires close monitoring and caution when used concomitantly with thrombolytic agents, such as alteplase or reteplase, due to an increased risk of bleeding.[31]

Abrocitinib

Cangrelor can potentiate the antiplatelet effect of abrocitinib. Therefore, the combination of these medications should be avoided.[32]

Anticoagulants

The administration of P2Y12 inhibitors with anticoagulants, such as heparin, warfarin, or direct oral anticoagulants, may increase the risk of bleeding. Therefore, clinicians should use caution when using this combination of medications.[33]

Contraindications

Cangrelor is contraindicated in individuals with known hypersensitivity or allergic reactions to cangrelor or its components. Cangrelor is contraindicated in cases of active pathological bleeding, including gastrointestinal bleeding or intracranial hemorrhage.[20]

Box Warning

The US Food and Drug Administration has issued no specific boxed warnings for cangrelor. However, clinicians should recognize that drug safety information can evolve over time.

Warnings and Precautions 

Bleeding risk: Cangrelor increases the risk of bleeding, which can be severe or even life-threatening.[34] Therefore, clinicians should exercise caution when administering cangrelor to patients at an increased risk of bleeding, including those with a recent history of surgical procedures, bleeding disorders, or significant trauma. Close monitoring for signs of bleeding and appropriate treatment strategies should be implemented to mitigate potential risks and ensure patient safety.

Thrombocytopenia:  Cangrelor can decrease platelet count, a condition known as thrombocytopenia. Therefore, regular monitoring of platelet counts is recommended, especially during prolonged use or in patients with risk factors for thrombocytopenia.

Surgical procedures: Cangrelor's antiplatelet effects can prolong bleeding time; therefore, clinicians should exercise caution when scheduling surgical procedures. The decision to discontinue cangrelor before a surgical procedure should be carefully considered, taking into account the patient's bleeding risk and the desired duration of antiplatelet effect.

According to the American Society of Regional Anesthesia and Pain Medicine guidelines, the risk of severe bleeding associated with a neuraxial block while the residual effect of cangrelor is present remains unknown. The guidelines also recommend removing neuraxial catheters before reinstituting cangrelor therapy postoperatively. The first postoperative dose of cangrelor should be administered 8 hours after removal of the neuraxial catheter.[35]

Monitoring

Patients receiving cangrelor should be closely monitored for signs of bleeding, both clinically and through laboratory testing, including a complete blood count. An advanced monitoring technique, the P2Y12 monitoring assay, can also be employed. The P2Y12 assay estimates the degree of platelet inhibition by P2Y12 inhibitors, such as cangrelor. The reference range for P2Y12 reaction units is 194 to 418. However, P2Y12 reaction unit results may be unreliable in patients with altered hematocrit, platelet counts, or fibrinogen levels. Therefore, clinicians should monitor hematocrit, platelet count, and fibrinogen levels during cangrelor infusion.[36]

Toxicity

Severe toxicity related specifically to cangrelor is rare.[37] Nevertheless, some potential toxicity concerns are associated with cangrelor use, including bleeding, allergic reactions, thrombocytopenia, and local site reactions. Results from a pooled analysis of the CHAMPION trials assessed data on cangrelor overdose. The analysis identified 36 patients who experienced an overdose of cangrelor. In most cases, the cangrelor dose did not exceed 2.5-fold the recommended dosage. Notably, only 1 patient who experienced an overdose had a severe bleeding event.[38]

Signs and Symptoms of Overdose

Common signs and symptoms of cangrelor overdose include bleeding and thrombocytopenia.

Management of Overdose

Treatment of cangrelor overdose involves providing supportive care and closely monitoring the patient's condition because no specific antidote is available for the drug.

• Stop the cangrelor infusion immediately and seek assistance from a rapid response team.[39]
• Monitor the patient's vital signs, including blood pressure, heart rate, and oxygen saturation.
• Perform continuous cardiac monitoring to assess for any arrhythmias or changes in the electrocardiogram.
• Consider platelet transfusion under the guidance of a hematologist in cases of severe bleeding or refractory thrombocytopenia to restore platelet function and aid in clot formation.
• Consult a toxicologist in severe cases.

Enhancing Healthcare Team Outcomes

Interdisciplinary collaboration and effective communication among these healthcare professionals are essential for optimizing patient outcomes and ensuring the safe use of cangrelor. Collaborative care supports comprehensive treatment, monitoring for potential adverse events, and adjustment of treatment plans to achieve the best possible patient outcomes. When cangrelor is administered to a patient, several disciplines may be involved in their care. The cardiologist plays a central role in administering cangrelor, as they determine the appropriate indication, dosage, and duration of therapy. In addition, the cardiology team monitors the patient's cardiovascular status, assesses the need for antiplatelet therapy, and evaluates the response to treatment.

Clinical pharmacists play a crucial role in ensuring the safe and effective use of cangrelor. They provide medication reconciliation, assess potential drug interactions, recommend appropriate dosing adjustments for patients with renal or hepatic impairment, and educate patients on their medications. Cardiothoracic surgeons may be involved in off-label uses that require cardiac surgical procedures. A hematologist consultation may be necessary for severe bleeding. Pathologists provide valuable input regarding the appropriate laboratory monitoring. Nurses should monitor the patient and inform the team about any adverse events.  

A strategic approach is equally crucial, involving evidence-based strategies to optimize treatment plans and minimize adverse effects. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices. Each healthcare professional must be aware of their responsibilities and contribute their unique expertise to the patient's care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of patients with cardiac ischemia.